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Abstract 21 
The study of the occurrence and fate of pharmaceutical compounds in drinking or waste 22 
water processes has become very popular in recent years. LC-MS/MS is a powerful 23 
analytical tool often used to determine pharmaceutical residues at trace level in water. 24 
However, many steps may disrupt the analytical procedure and bias the results. A list of 27 25 
environmentally relevant molecules, including various therapeutic classes and 26 
(cardiovascular, veterinary and human antibiotics, neuroleptics, non-steroidal anti-27 
inflammatory drugs, hormones and other miscellaneous pharmaceutical compounds) was 28 
selected. In this work, a method was developed using Ultra Performance Liquid 29 
Chromatography coupled to tandem Mass Spectrometry (UPLC-MS/MS) and solid phase 30 
extraction (SPE) to determine the concentration of the 27 targeted pharmaceutical 31 
compounds at the nanogram per liter level. The matrix effect was evaluated from water 32 
sampled at different treatment stages. Conventional methods with external calibration and 33 
internal standard correction were compared to the standard addition method. An accurate 34 
determination of pharmaceutical compounds in drinking water was obtained by the 35 
OFX (neutral extraction)
0
20
40
60
80
100
120
140
160
-20 0 20 40 60 80 100 120
Co
n
c
e
n
tr
at
io
n
 
ca
lc
u
la
te
d 
fro
m
 
IS
 
a
n
d 
e
x
te
rn
a
l c
a
lib
ra
tio
n
 
(µg
 
/L
)
Added amount (µg/L)
CAF (neutral extraction)
19 ng/L
16 ng/L
8 ng/L
22 ng/L
Theoretical slope
withoutmatrix effect
Overestimation
Underestimation
standard addition method associated with UPLC-MS/MS. The developed method was used 36 
to evaluate the occurrence and fate of pharmaceutical compounds in some drinking water 37 
treatment plants (DWTPs) in the west of France. 38 
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1. Introduction  44 
Human and veterinary uses of pharmaceutical compounds lead to the releasing of bioactive 45 
compounds into the aquatic environment. Metabolization rates depend on the nature of the 46 
drugs and may range from 1 – 96 % [1]. Non-metabolized drugs are thus excreted in urine 47 
as free or conjugated forms [2,3], and collect in the waste water network. Pharmaceutical 48 
compounds are not completely removed during waste water treatment [4-7]. The efficiency 49 
of the process depends on the operating conditions and the nature of the molecule [6]. For 50 
example, conventional treatment with activated sludge effectively eliminates ibuprofen, and 51 
benzafibrate while diclofenac, carbamazepine and sulfamethoxazole are scarcely removed 52 
[8]. Some pilot scale studies have been carried out using a membrane bioreactor in an 53 
attempt to improve the outcome; these processes were found to be more efficient than 54 
activated sludge reactors at removing pharmaceutical compounds [8,9]. The disinfection of 55 
treated waste water can also improve the elimination rate of pharmaceutical compounds 56 
[10]. An indirect way of introducing these compounds into the environment  is via 57 
agricultural activities. Sludge from waste water treatment plants may be spread on fields as 58 
a fertilizer and the pharmaceutical compounds which can be immobilized in this sludge 59 
may then contaminate the soil [11]. The veterinary use of drugs can lead to a direct 60 
environmental contamination by the discharge of untreated effluent from intensive animal 61 
farming. Direct soil contamination can occur by the excretion of urine and feces by farm 62 
animals onto fields [12]. Rainfall and soil leaching may then transport pharmaceutical 63 
compounds from the soil to the aquatic compartment [13]. Intensive livestock farming is 64 
one of the main economic sectors of Brittany area (north-west France). Moreover, a large 65 
proportion of the population uses a non-collective waste water treatment to clean household 66 
effluent, so drinking water treatment specialists are beginning to be concerned about the 67 
potential contamination of water resources by pharmaceutical compounds. Some recent 68 
study shows that  69 
Recently the French Agency for Food Health Safety (AFSSA) determined,  the main 70 
relevant molecules to examine in drinking water from the total amount consumed and their 71 
properties in the aqueous phase [14]. Based on this work, a wide measurement campaign 72 
was carried out by the French Agency for Environmental and Occupational Health Safety 73 
(ANSES) [15]. From the 150 molecules included in the ANSES study, only 20 were found 74 
at concentrations above the the limit of quantification (LOQ) and 11 between the limit of 75 
detection (LOD) and the LOQ. Only these molecules were selected for the present work. 76 
Accurate trace determination of emerging contaminants in the environment is an important 77 
analytical challenge. The first obstacle is associated with the gap between environmental 78 
concentrations and the quantification limits of analytical systems. Pharmaceutical 79 
compounds concentrations range from LOQ of 2000 ng L-1 to LOQ of 200 ng L-1 in surface 80 
water and drinking water, respectively [16-19] while the LOQ of conventional MS-MS 81 
apparatus (without a pre-concentration step), are typically in the µg L-1 range. 82 
Consequently, a concentration step is needed before analysis; solid phase extraction (SPE) 83 
is the method of choice for the determination of emerging contaminants in water [20-22]. 84 
The second obstacle, resulting from the use of SPE, is the concomitant extraction of 85 
interfering species and the target molecules. Polar organic pollutants are commonly 86 
determined by liquid chromatography with tandem mass spectrometry (LC-MS/MS). 87 
However, interfering species may affect the analytical procedure at different stages: i) some 88 
compounds may react with targeted molecules during the sampling and storage periods, ii) 89 
organic or inorganic solutes may affect the yield of SPE extraction, iii) natural organic 90 
matter may coeluate with targeted compounds which leads to a signal disrupting with 91 
under/overestimation or false positive samples [23]. The study presented here deals with 92 
the development of the method including an evaluation of the matrix effect. Accurate 93 
determination of pharmaceutical compounds in drinking water was performed by the 94 
standard addition method associated with ultra pressure liquid chromatography and tandem 95 
mass spectrometry. The method was used to evaluate the occurrence and fate of 96 
pharmaceutical compounds in some drinking water treatment plants (DWTP) in the west of 97 
France. 98 
2. Materials and methods 99 
2.1. Stock solution and standard preparation. 100 
Stock solutions of individual pharmaceutical compounds were prepared by diluting reagent-101 
grade chemicals (Sigma Aldrich) in methanol (Fisher). Ultra pure water (UPW) was 102 
provided by an ElgaPureLab System (18.2 MΩ.cm). Chromatographic solvents (MeCN; 103 
MeCN with 0.1 % formic acid) were purchased from JT Baker (LC-MS grade) and were 104 
used in association with UPW or UPW with 0.1 % formic acid. A standard mix solution (5 105 
and 10 mg L-1 in MeOH) was prepared from individual stock solutions including all the 106 
targeted molecules except amoxicillin, caffeine, oxazepam and internal standards. The 107 
solution was then divided into a series of vial and stored at -20°C in the dark. The vial 108 
containing the standard mix was placed at room temperature before use and the unused 109 
amount was discarded. The standard mix was used to prepare both injections standard for 110 
the external calibration and spiked solutions for the standard addition method. Amoxicillin, 111 
caffeine, and oxazepam stock solution were prepared in UPW, MeOH and MeCN, 112 
respectively. Calibration curves were plotted using eight-level standard solutions (1, 2, 5, 113 
10, 25, 50, 100, 200 µg L-1 and up to 2000 µg L-1 for caffeine). The chromatographic 114 
sequence consisted of the injection of standards and samples as follows: calibration curve - 115 
first samples analysis - calibration curve - second samples analysis - calibration curve. In 116 
addition a middle-range standard solution was injected every 10 injections in order to verify 117 
the absence of significant signal deviation.  118 
2.2. Sample preparation  119 
On arrival at the laboratory, water samples stored in 2-L amber glass bottles were filtered 120 
through a 0.45 µm cellulose acetate membrane to remove suspended matter and colloids. 121 
Samples were then stored in the dark before preparation and analysis. All the analyses were 122 
carried out within a maximum storage period of 5 days. Solid phase extraction was 123 
performed by filtering 200 mL of sample into a 6 mL Oasis HLB cartridge (6 cc, 150 mL, 124 
Waters). HLB cartridges were conditioned with 5 mL of MeCN and rinsed with 5 mL of 125 
UPW prior to the extraction step. Extraction was conducted by the filtering 200 mL of 126 
sample (acidified at pH = 2 with sulfuric acid or not) under reduced pressure at a flow rate 127 
of approximately 3 mL min-1. The cartridge was cleaned with 5 mL UPW or UPW acidified 128 
at pH = 2 (depending on the extraction method used) and then eluted with 4 mL MeCN. 129 
The extract was evaporated under nitrogen flow to obtain a final volume of 100 µL. 100 µL 130 
of internal standard (caffeine-13C3 and ibuprofene-d3, 100 µg L-1 in MeCN/UPW 10/90) 131 
was added prior to LC-MS/MS analysis. 132 
2.3. Liquid Chromatography Tandem Mass Spectrometry 133 
All samples were analyzed using LC/MS/MS equipped with an electrospray ionization 134 
source (ESI). The analytical equipment consisted of an ultra pressure liquid 135 
chromatography system (Acquity, Waters) equipped with a reversed phase UPLC column 136 
from Waters (Acquity C18 BEH, 100 mm x 2.1 mm ID, 1.7µm) and thermostated at 45°C. 137 
The autosampler temperature was set at 4°C, and the injection volume was 5 µL in the full-138 
loop mode. The mass spectrometer (Quattro Premier; Micromass) general operating 139 
conditions were : cone gas (N2, 50 L h-1, 120°C) -desolvation gas (N2, 750 L h-1, 350°C); 140 
collision gas (Ar, 0.1 mL min-1); capillary voltage (3000 V). The advanced mass parameters 141 
(cone and collision cell voltage) are further described in Table 1. 142 
3. Results and discussion 143 
3.1. Optimization of mass spectrometry 144 
Infusion is the first step of method development by liquid chromatography tandem mass 145 
spectrometry. It consists of a direct analysis of a pure diluted solution without separation in 146 
order to record the mass spectrum of each selected compound and to determine the MRM 147 
transitions. During this step the MS parameters such as cone voltage, and collision cell 148 
energy were optimized for each compound in order to achieve the maximum sensitivity. 149 
Table 1 shows the results obtained for the 29 molecules studied here; 3 internal and 150 
recovery standards are also included. ESI is soft ionization technique which allows the 151 
selection of a pseudo-molecular ion as the parent ion for MRM transitions; ESI was used in 152 
both the negative and positive mode. The positive mode was selected for most of the 153 
molecules while 9 analytes were ionized under the negative mode. The pseudo-molecular 154 
ion ([M+H]+ or [M-H]-) was selected as the parent ion. When possible, simple fragment 155 
loss, such as water or carbon dioxide, was selected for the quantification or confirmation 156 
transition (parent ion  daughter ion for the quantification and second daughter ion for 157 
confirmation). Only 1 transition was found for ibuprofen and ibubuprofen-d3. 158 
3.2. Chromatographic conditions and calibration 159 
UPLC with a BEH C18 column was performed with a gradient of ultra-pure water / 160 
acetonitrile at 400 µL min-1. The effect of formic acid addition on the chromatographic 161 
separation was also evaluated. The starting eluent composition consisted of 19 % 162 
acetonitrile for 1 minute, which was then linearly increased to reach 95.5 % at 7.5 minutes. 163 
A final eluent containing 95.5 % acetonitrile for 2 minutes was used to clean the column 164 
and prevent any parasite peaks. In order to obtain an acceptable detection of all the 165 
molecules, 2 chromatographic conditions, with and without formic acid addition, to 166 
promote ionization, were needed (Figure 1). Separation was achieved in 6 minutes with a 167 
complete chromatographic run of 12 minutes. Caffeine-13C3 (CAF-13C3) and ibuprofen-d3 168 
(IBU-d3) were used as the internal standard for quantification under the positive and 169 
negative ionization modes, respectively. Moreover, a recovery standard (ketoprofen-d3) was 170 
added prior to the solid phase extraction; no correction relative to ketoprofen-d3 was made 171 
and its use was only indicative. External calibration curves were used for the determination 172 
of relative response factors (RRF) for each analyte according to the following equations:
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3.3. Linearity and quantification limits 174 
Recovery rates (RR), linearity and quantification limits were determined at environmentally 175 
relevant concentrations; the results are summarized in Table 1. Because those obtained with 176 
UPW and surface water samples cannot be easily compared, the evaluation of the basic 177 
parameters of the validation method was carried out without organic interfering species 178 
(UPW or Evian water). Linearity was validated between 5 – 200 µg L-1 in the vial (injected 179 
volume = 5 µL) which corresponds to 5 – 200 ng L-1 in the starting sample if the RR is 180 
considered equal to 100 %. External calibration curves (8 levels + 1 blank) were also used 181 
to determine the standard deviation on the instrumental method; the SD presented here does 182 
not include the deviation on the SPE step. The results show that acceptable relative 183 
standard deviations lower than 10 % were obtained for most of the pharmaceutical 184 
compounds. However poor-quality results were obtained for hormones with a relative 185 
standard deviation ranging from 40 to 60 %. 186 
The evaluation of instrumental detection (S/N = 3) and quantification limits (S/N = 10) 187 
(IDL and IQL) was performed by the injection of 10 blank samples (Evian water). From the 188 
29 targeted compounds, IQL lower than 4 µg L-1 were obtained for 27 of them, 189 
demonstrating that determination in the nanogram per liter range requires a concentration 190 
factor of up to 1000. Higher IQL values were obtained for ethinylestradiol and salicylic 191 
acid (8 and 24 µg L-1, respectively). It should be underlined that the evaluation of the limit 192 
of quantification (LOQ) by this method (apparatus LOQ without the SPE step and in the 193 
absence of interfering compounds) is not directly transposable for the determination of 194 
pharmaceutical residues in surface water. Nevertheless, this quick approach demonstrates 195 
that our method enables pharmaceuticals in surface and drinking water to be determined at 196 
an environmentally relevant concentration. 197 
3.4. SPE extraction 198 
Solid phase extractions were performed with Oasis HLB cartridges by filtering 200 mL of 199 
0.45 µm pre-filtered sample in order to obtain a concentration factor of 1000. Because the 200 
selected molecules can be assumed to be weakly basic or weakly acid compounds, the 201 
effect of sample the acidification on the extraction yield was evaluated in UPW. Standard 202 
solutions each containing 100 ng L-1 of analyte were filtered onto an HLB cartridge as 203 
previously described. Recovery rates were determined using the internal standards caffeine-204 
13C3 and ibuprofen-d3 for the analysis under ESI+ and ESI-, respectively (Figure 2).  205 
The results of the extraction experiments are summarized in Table 1. Acetaminophen, 206 
caffeine, carbamazepine, and oxazepam were almost quantitatively (80–120%) recovered in 207 
conditions all investigated. These analytes are assumed to be neutral drugs, which explains 208 
their high recovery yields under acidic and neutral extractions. In spite of a pKa value of 209 
4.16, a similar result was obtained for losartan. Amphoteric drugs such as danofloxacin and 210 
ofloxacin exhibited higher recovery yields under acidic extraction than under neutral 211 
conditions. Thus, for these compounds, the SPE is controlled by the carboxylic function 212 
and the amino group does not affect the extraction yield. The opposite effect was observed 213 
for amoxicillin where no acceptable recovery yields were obtained under acidic or neutral 214 
conditions. In this case, the controlling group should be the amino acid function and 215 
extraction under basic conditions could increase the recovery yield. Extraction under acidic 216 
conditions was selected for most of the carboxylic acids, for example ibuprofen, ketoprofen 217 
and salicylic acid. In contrast to acidic drugs, basic drugs containing an amino group (i.e. 218 
atenolol, naftidrofuryl and lincomycin) had comparatively higher recoveries under neutral 219 
conditions due to the formation of ammonium derivatives at low pH values.  Except for 220 
amoxicillin, the combination of both acidic and neutral extractions provided acceptable 221 
recovery rates for all the analytes. However the recovery rates determined in UPW 222 
experiments could be dramatically affected by the presence of interfering species (i.e. 223 
natural organic matter). 224 
3.5. Evaluation of the matrix effect 225 
The presence of organic or inorganic substances could lead to an analytical bias. Natural 226 
Organic Matter (NOM) is a complex mixture of polyfunctional macromolecules [24] which 227 
may disturb the SPE step, or MS ionization. From the various effects attributable to the 228 
presence of NOM some phenomena can be described such as competitive adsorption on the 229 
HLB phase [25], the formation of NOM-analyte complexes [26] and the modification of the 230 
analyte ionization efficiency in the MS source [27]. Although the presence of NOM is 231 
frequently associated with an underestimation of the targeted analytes (decreasing the 232 
extraction yield and/or the ionization efficiency), the opposite effect may also occur, 233 
despite not being well documented. 234 
In order to evaluate the effect of NOM, the recovery rates obtained in pure water were 235 
compared with those obtained in surface water. Four surface waters (used to supply 236 
drinking water treatment plants) were spiked with stock solutions of pharmaceutical 237 
compounds to obtain a concentration of 100 ng L-1 of each targeted analyte. Because 238 
surface water may initially contain some pharmaceutical residues, unspiked samples were 239 
also analyzed to determine the signal contribution due to the presence of analyte in surface 240 
water; signal was then corrected to be specific to the added amount of analyte. Figure 3 241 
shows the comparison between the recovery rates obtained in pure water and those obtained 242 
in raw water (surface water) from the drinking water treatment plant A and B (DWTPA-243 
RW ; DWTPB-RW). These results demonstrate that the determination of pharmaceutical 244 
compounds at trace level is very influenced by the water quality. For some compounds, 245 
such as tylosin, atenolol, losartan, ibuprofen and amoxicillin, no significant matrix effect 246 
was observed. The recovery rate determined for amoxicillin in surface water was quite 247 
similar to that observed in pure water. However, due to its very low value, a possible matrix 248 
effect may be masked. The absence of a detectable matrix effect on ibuprofen can be 249 
explained by the fact that this compound was quantified relative to ibuprofen-d3. Figure 3 250 
shows a significant underestimation of diclofenac and -estradiol in surface water. In 251 
contrast, many compounds such as carbamazepine and epoxy-carbamazepine were 252 
overestimated. The recovery rate observed for oxazepam in pure water (105 %) was not 253 
significantly different from that observed in DWTPA-RW (104%) but a significant 254 
overestimation was observed in DWTPB-RW (145 %). In the case of ethinylestradiol, 255 
recovery rates in pure water and DWTPA-RW (108 and 89 %, respectively) were quite 256 
similar whereas a significant underestimation was measured in DWTPB-RW (59 %). 257 
Clearly, the recovery rates determined with pure water are not transposable to surface 258 
water. The recovery rates obtained with surface water differ depending on the nature of the 259 
NOM. Therefore, a classical approach with external calibration and internal/external 260 
standard correction is not sufficiently accurate for the multi-residue analyses of 261 
pharmaceutical compounds at trace level in water. 262 
3.6. Standard addition method 263 
The standard addition method (SAM) is very efficient for correcting the matrix effect and 264 
providing an overall evaluation of this effect on both the SPE step and MS ionization. 265 
Moreover, it can be used even if the molecules were not initially present in water. All 266 
samples were spiked with stock solutions containing the 29 targeted pharmaceuticals (not 267 
spiked; 50 and 100 ng L-1). The conventional quantification method (external calibration 268 
with internal standard correction) was compared with SAM results according to the 269 
following equations: 270 
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Figure 4.a shows an example of matrix effect evaluation for some molecules not detected in 271 
the raw water of DWTP A. In the absence of a matrix effect, a theoretical slope equal to 1 272 
should be obtained; in the present case (DWTP A-RW), some compounds such as estrone 273 
and sulfadimerazine were weakly affected by water quality and interfering species. 274 
Conversely, the low recovery rate obtained for diclofenac could be attributed to a decrease 275 
in the extraction yield and/or signal suppression caused by a modification of ionization in 276 
the ESI source. The inverse effect was observed for naftidrofuryl, for which conventional 277 
quantification leads to an overestimation. Because no signal attributable to naftidrofuryl 278 
was observed in the non-spiked sample, the overestimation could not be due to the co-279 
elution of a false-positive compound, but it could be caused by an ion enhancement effect. 280 
This type of matrix effect has previously been reported in the literature [23] with similar 281 
compounds (basic drugs) in surface water. Moreover, Dams et al. [28] underlined that ESI 282 
was especially susceptible compared to APCI. The same approach was adopted with 283 
compounds initially observed in the non-spiked sample (Figure 4.b). In the case of caffeine, 284 
similar results were obtained with the conventional method (19 ± 3 ng L-1) and SAM (16 ± 285 
3 ng L-1). However, the quantification of ofloxacin by the conventional method (8 ± 2 ng L-286 
1) led to a significant underestimation (SAM: 22 ± 3 ng L-1) of its concentration in drinking 287 
water.  288 
The standard addition method was used to determine the concentration of pharmaceuticals 289 
at different treatment stages from raw water to drinking water in four drinking water 290 
treatment plants (DWTPs). The matrix effect was evaluated on a total of 16 samples. The 291 
slopes of the curves, obtained with the 29 targeted compounds in the different samples 292 
(example given in Figure 4), are summarized as a box plot (Figure 5.). These results 293 
underline that the chromatographic method proposed here fails to determine the 29 targeted 294 
compounds accurately. Recovery rates obtained for amoxicillin were lower than 3 %, which 295 
could be explained by the extraction step (SPE yield lower than 7 % in pure water). 296 
Moreover, in some cases amoxicillin was not detected in the spiked samples (50 and 100 ng 297 
L-1), so a competitive effect on the adsorption step and/or signal suppression could be 298 
suggested in addition to poor SPE efficiency. Not only was salicylic acid dramatically 299 
affected by the matrix effect, but antagonistic effects (signal suppression and enhancement) 300 
were also observed with similar water qualities: large signal suppression was observed in 301 
the raw water of DWTP A while signal enhancement occurred after the sand filtration step 302 
of the same DWTP. A review of the chromatographic data also reveals an abnormally large 303 
area associated with salicylic acid. In some cases, the calculated concentrations with both 304 
the conventional and standard addition methods reach the milligram per liter range, so a 305 
cross-talk effect could be suggested. As smaller deviations between the conventional 306 
method and SAM were observed for compounds which were quantified relative to their 307 
analogous IS (ibuprofen, caffeine), the results obtained here demonstrate that the correction 308 
of the matrix effect with internal standards cannot easily be transposed to other compounds. 309 
In spite of the efficiency of the SAM to correct the matrix effect, amoxicillin and salicylic 310 
acid were removed from the quantifiable list of compounds; thus only the 27 of the 29 311 
pharmaceutical compounds initially targeted were accurately quantified by the method 312 
proposed here. 313 
3.7. Application to drinking water analysis 314 
Concentrations of pharmaceutical compounds in the samples from DWTP were calculated 315 
from Equation 3. The results obtained during the sampling campaign show that only 13 316 
molecules were observed at concentrations above the LOD at least once. Figure 6 317 
summarizes the occurrence and fate of the detected compounds in the four sampled 318 
DWTPs. Concentrations observed ranged from the LOQ to 95 ng L-1 (hydroxy-ibuprofen in 319 
DWTP D). From the 13 detected molecules, only 3 pharmaceutical compounds were 320 
quantified in all samples (caffeine, ofloxacin, hydroxy-ibuprofen). 9 molecules were 321 
detected with concentrations lower than the LOQ and 3 of these were only observed in raw 322 
water (losartan, epoxy-carbamazepine and ketoprofen). Erythromycin, tylosin, 323 
progesterone, hydrochlorothiazide and ibuprofen were detected (<LOQ) at different stage 324 
of the water treatment. Finally 6 targeted compounds were never detected during the 325 
sampling campaign (lincomycin, diclofenac, estrone, pravastatin, atenolol and 326 
doxycycline). It should be underlined that the SAM approach identified significant signal 327 
inhibition of danofloxacin and ofloxacin in the raw water of DWTP B and in the 328 
chlorinated water of DWTP A. Since the spiking of danofloxacin and ofloxacin does not 329 
lead to a significant increase in peak area associated with these compounds, their 330 
quantification was not possible. Nevertheless, ofloxacin and danofloxacin were accurately 331 
determined after sand filtration at a concentration ranging from 5 – 10 ng L-1, so it could be 332 
suggested that they were initially present in the raw water. This particular case reinforces 333 
the efficiency of the SAM approach for identifying matrix effects and facilitating the 334 
interpretation of results. Only the quantified compounds were considered when examining 335 
the effect of the water treatment process on the removal of pharmaceuticals (Figure 6). 336 
From the results obtained, 3 classes of pharmaceuticals can be defined. Several compounds, 337 
such as caffeine, trimethazine and oxazepam were partially removed during the treatment 338 
process. The clarification step (coagulation-flocculation-sand filtration) seemed to be most 339 
efficient for eliminating pharmaceutical compounds. In fact, acetaminophen, 340 
carbamazepine, amlodipine, sulfamethazine, -estradiol and ethinylestradiol were 341 
completely removed after this step. These data are consistent with the work of Vieno et al. 342 
who demonstrated that coagulation of surface water with ferric sulfate could efficiently 343 
remove some pharmaceutical residues [29]. A second class of compounds can be defined as 344 
refractory pollutants; ofloxacin, danofloxacin and naftidrofuryl were not significantly 345 
eliminated during drinking water production. The third group of molecules consists of 346 
metabolites formed during water treatment; only hydroxy-ibuprofen in the present study. A 347 
large increase in hydroxy-ibuprofen concentration was observed in all the DWTPs 348 
considered although ibuprofen was never observed at a concentration level above the LOQ. 349 
The gulcuronide conjugate of ibuprofen is the main metabolite from ibuprofen metabolism 350 
[3]. Cleavage of this conjugate could occur during water treatment releasing the free form 351 
of ibuprofen, which could then be oxidized to produce hydroxy-ibuprofen. A similar 352 
mechanism has previously been proposed by Ternes et al. to explain the formation of 353 
estrone from the glucuronide conjugate of -estradiol in a waste water treatment plant 354 
[[30]]. 355 
4. Conclusion 356 
In this study, a multiresidue analysis of pharmaceuticals at trace level in surface and 357 
drinking water involving a solid phase extraction followed by UPLC-MS/MS determination 358 
was developed. Matrix effects were examined for 29 pharmaceuticals in 16 samples. Matrix 359 
effects were severe, even with internal standard correction, so the standard addition method 360 
was necessary for an accurate determination. The analytical method developed here was 361 
then used to evaluate the occurrence and fate of drug residues in drinking water treatment 362 
plants. Further studies will be conducted to confirm the effect of the water treatment 363 
process on the elimination of pharmaceutical residues. 364 
365 
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Table 1. Summary of the method development 
Therapeutic class Molecule MW (g/mol) 
ESI 
(+ / -) 
MRM transitions (m/z) 
r2 SD LOD (µg L-1) 
LOQ 
(µg L-1) 
SPE UPLC 
Parent ion. (CVa) Quant. ion (CEb) Conf. ion (CE)  
C
a
rd
io
v
a
sc
u
la
r 
Amlodipine (AML)* 567.05* + 409.6 (18) 238.1 (11) 292.2 (13) 0.994 0.109 0,3 1,0 cA A 
Atenolol (ATE) 266.34 + 267.0 (34) 145.0 (26) 74.0 (23) 0.986 0.118 0,2 1,0 dN A 
Losartan (LOS)* 461.00* + 423.6 (30) 405.2 (12) 207.0 (22) 0.987 0.100 0,4 1,0 eN+A A 
Naftidrofuryl (NAF)* 473.56 + 384.6 (40) 99.7 (21) 84.7 (25) 0.992 0.106 1,4 2,0 N A 
Pravastatin (PRA)* 446.51 - 423.2 (34) 100.6 (23) 321.1 (16) 0.988 0.119 0,1 1,0 N N 
Trimetazidine (TRI)* 339.26 + 267.4 (21) 180.9 (16) 165.8 (26) 0.995 0.082 0,2 1,0 N A 
A
n
tib
io
tic
s 
 
H
u
m
a
n
 
Amoxicillin (AMO) 365.40 + 366.5 (16) 113.7 (24) 349.0 (10) 0.980 0,176 0,4 1,0 A A 
Doxycycline (DOX)* 512.94 + 445.5 (30) 428.2 (18) 153.8 (28) 0.986 0,103 0,7 2,0 A A 
Erythromycin (ERY) * 769.96* + 734.2 (28) 158.0 (30) 576.2 (19) 0.987 0,123 0,0 1,0 N A 
Ofloxacin (OFX) 361.37 + 362.0 (34) 318.0 (19) 261.0 (28) 0.985 0,155 0,9 2,0 A A 
V
et
er
in
a
ry
 Danofloxacin (DANO) 357.38 + 358.5 (35) 314.0 (19) 283.0 (25) 0.976 0,210 1,8 4,0 A A 
Lincomycin (LINCO)* 461.01 + 407.6 (40) 125.9 (28) 359.3 (18) 0.984 0,125 0,0 1,0 N A 
Sulfadimerazine (SFZ) 278.33 + 279.4 (29) 185.9 (16) 91.7 (26) 0.979 0,133 0,3 1,0 N A 
Tylosin (TYL) * 1066.19* + 917.0 (60) 174.0 (37) 773.0 (29) 0.994 0,088 0,3 1,0 N A 
Neuro. 
Carbamazepine (CBZ) 236.27 + 237.1 (28) 194.0 (19) 179.0 (39) 0.976 0.122 0,1 1,0 N+A A 
Epoxycarbamazepine (Ep-CBZ) 252.27 + 253.3 (28) 179.9 (28) 236.0 (12) 0.988 0.111 0,3 1,0 A A 
Oxazepam (OZP) 286.71 + 287.4 (34) 241.0 (20) 269.1 (14) 0.985 0.109 0,5 2,0 N+A A 
NSAID 
Diclofenac (DICLO) 294,14 + 296,1 (22) 250,0 (10) 214,1 (25) 0.987 0.120 0,2 1,0 N A 
Ibuprofen (IBU) 206,28 - 205,0 (17) 161,0 (7) / 0.965 0.188 0,2 1,0 A N 
Hydroxyibuprofen (OH-IBU) 222,28 - 221,2 (19) 177,0 (9) 158,7 (13) 0.994 0.103 0,8 2,0 A N 
Ketoprofen (KETO) 254,28 + 255,0 (29) 209,0 (12) 105,0 (22) 0.989 0.085 0,3 1,0 A A 
Salicylic acid (SCA) 138,12 - 137,0 (30) 92,6 (14) 64,7 (28) 0.984 0.100 9,1 24,0 A A 
Misc. 
Acetaminophen (PARA) 151,16 + 152,0 (25) 110,0 (15) 90,0 (10) 0.986 0.094 1,3 4,0 N+A A 
Caffeine (CAF) 194,19 + 195,1 (37) 137,7 (18) 109,7 (22) 0.987 0.129 1,8 3,0 N+A A 
Hydrochlorothiazide (HCTZ) 297,74 - 296,2 (42) 77,6 (28) 204,8 (22) 0.981 0.170 0,1 1,0 A N 
Hormones 
Ethinylestradiol (EE) 296,40 - 295,2 (54) 144,9 (40) 183,0 (35) 0.873 0.406 2,8 8,0 A N 
17-Estradiol (E) 272,38 - 271,1 (50) 145,0 (38) 183,0 (41) 0.741 0.611 0,4 1,0 A N 
Estrone (EO) 270,37 - 269,1 (53) 145,0 (35) 183,0 (36) 0.875 0.393 0,5 1,0 A N 
Progesterone (PGT) 314,46 + 315,2 (32) 97,0 (24) 109,0 (26) 0.992 0.097 0,2 1,0 N A 
IS 
Ketoprofen-d3 (KETO-d3) 257,30 + 258,4 (25) 212,0 (15) 179,8 (23)     N+A A 
Caffeine-13C3 (CAF-13C3) 195,19 + 198,2 (35) 139,7 (20) 111,7 (22)     / A 
Ibuprofene-d3 (IBU-d3) 209,30 - 208,2 (18) 163,9 (7) /     / N 
aCone Voltage in volt; bCollision energy in volt; cSPE extraction at pH = 2, dSPE extraction at pH = 7; eMean value of the 2 methods. *molecule whose molecular weight of the 
commercial product purchased does not correspond to the molecular weight of the active compound (i.e. amlodipine besylate – MW = 567.05 versus amlodipine – MW = 408.87)
 a)
b) 
 
Figure 1. Example of chromatogram obtained with a standard mix solution at 100 µg L-1. Chromatograms 
obtained with (a) addition of 0.1% formic acid and (b) without acidification. 
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Figure 2. Effect of pH during SPE extraction on the recovery rate in pure water. 
[Analyte] = 100 ng L-1 ; concentration factor = 1000. 
 
  
0
50
100
150
200
A
M
O
A
T
E
T
R
I
PA
R
A
L
IN
CO CA
F
O
FX SF
Z
D
A
NO SC
A
D
O
X
E
p-
CB
Z
E
R
Y
CB
Z
T
Y
L
O
Z
P
A
M
L
O
L
O
S
NA
F
K
E
T
O
K
E
T
O
-
…
D
IC
L
O
PG
T
H
CT
Z
O
H
-
IB
U
PR
A BE EE E
O
IB
U
R
ec
o
v
er
y 
R
a
te
 
(%
)
Neutral
Acid
  
 
 
 
 
Figure 3. Effect of water quality on the recovery rate. [Analyte] = 100 ng L-1 ; 
concentration factor = 1000 ; letters in parentheses refer to the SPE mode i.e. Acid and/or 
Neutral conditions. 
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Figure 4. Comparison of concentrations determined by external calibration with internal 
standard correction and standard addition method. Example of compounds (a) not detected and 
(b) detected in DWTP A-RW.  
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Figure 5. Overall evaluation of the matrix effect in multiresidue analysis of pharmaceutical 
compounds in surface and drinking water. 
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Figure 6. Fate and occurrence of pharmaceutical compounds at different stages of the drinking 
water process. Raw Water (RW), Stored Raw Water (SRW), Coagulation-Flocculation (CF), Sand 
Filtration (SF), Granular Activated Carbon (GAC) and Chlorination (CL2). DWTP A and B include 
an ozonation step before GAC filtration; DWTP B and D include a powder activated carbon reactor 
in the clarification step and a membrane ultra-filtration (UF) as a polishing treatment before 
chlorination.  
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